Introduction
============

Afibrinogenemia is a rare bleeding disorder with an estimated prevalence of 1:1,000,000.[@b1-vhrm-5-843],[@b2-vhrm-5-843] It is an autosomal recessive disease and most patients are commonly descendent of consanguineous marriages.[@b1-vhrm-5-843]--[@b3-vhrm-5-843] Afibrinogenemia results from mutations in any of the 3 genes (FGA, FGB and FGG) that encode the 3 polypeptide chains of fibrinogen (Aα, Bβ and γ) and are located in a 50 kb region on 4q31.3.[@b4-vhrm-5-843] These mutations affect the synthesis, assembly, intracellular processing, stability or secretion of fibrinogen.[@b4-vhrm-5-843] Fibrinogen plays an important role in clot formation through its conversion to fibrin by the action of thrombin.[@b5-vhrm-5-843],[@b6-vhrm-5-843] It is also important in primary hemostasis since it contributes to platelet aggregation by binding to glycoprotein IIb/IIIa on the activated platelet surface.[@b5-vhrm-5-843],[@b6-vhrm-5-843] The diagnosis of afibrinogenemia is based on the presence of prolonged prothrombin, thrombin, reptilase and activated partial thromboplastin time, undetectable functional fibrinogen and absence or trace amounts of immunoreactive fibrinogen.[@b5-vhrm-5-843] Platelet adhesion and ADP-induced platelet aggregation are also impaired in these patients whereas thrombin- and collagen-stimulated platelet aggregation is normal.[@b7-vhrm-5-843]--[@b10-vhrm-5-843]

We review the principal clinical manifestations and the management of patients with afibrinogenemia. We also discuss the case for prophylactic treatment and the management of pregnancy in these patients.

Clinical manifestations
=======================

The commonest manifestations of afibrinogenemia are umbilical stump bleeding (which can be life threatening) and bleeding from mucosal surfaces, particularly menorrhagia, epistaxis and bleeding in the oral cavity.[@b3-vhrm-5-843] Musculoskeletal bleeding (including hemarthroses) is observed in around half of the patients[@b3-vhrm-5-843],[@b11-vhrm-5-843] and in some series it was more frequent than mucosal bleeding.[@b12-vhrm-5-843] These discrepant results on the relative frequency of bleeding complications are partly due to the small number of patients included in the reported series.[@b3-vhrm-5-843],[@b12-vhrm-5-843] Bleeding from the gastrointestinal and urinary tract is less frequent[@b3-vhrm-5-843] whereas intracranial bleeding is rare.[@b3-vhrm-5-843],[@b12-vhrm-5-843]--[@b15-vhrm-5-843] However, recurrent episodes of intracranial hemorrhage have been reported.[@b12-vhrm-5-843],[@b14-vhrm-5-843]--[@b16-vhrm-5-843] Hemoperitoneum and hemorrhagic corpus luteum following the rupture of a follicle during ovulation are other rare manifestations.[@b13-vhrm-5-843],[@b17-vhrm-5-843]--[@b20-vhrm-5-843] The bleeding tendency is highly variable in afibrinogenemia (ranging between very few up to several episodes/year) even among patients with the same mutation.[@b5-vhrm-5-843],[@b12-vhrm-5-843],[@b21-vhrm-5-843] The presence of modifier genes (yet unidentified) or the coexistence of thrombophilic disorders has been implicated as an explanation for this variability.[@b21-vhrm-5-843] Besides spontaneous bleeding, bleeding after minor trauma and excessive bleeding during interventional procedures are other principal manifestations of afibrinogenemia.[@b2-vhrm-5-843],[@b3-vhrm-5-843],[@b11-vhrm-5-843]

Paradoxically, spontaneous thrombotic complications have also been reported in patients with afibrinogenemia, including thrombosis in peripheral arteries and in cerebral and hepatic veins.[@b3-vhrm-5-843],[@b22-vhrm-5-843],[@b23-vhrm-5-843] Fibrin down-regulates thrombin generation by reducing prothrombin activation and also binds and sequesters thrombin.[@b24-vhrm-5-843],[@b25-vhrm-5-843] This antithrombin activity of fibrin (antithrombin I) is absent in patients with afibrinogenemia, who exhibit increased prothrombin activation and thrombin generation. [@b7-vhrm-5-843],[@b24-vhrm-5-843],[@b25-vhrm-5-843] In addition, free thrombin may stimulate platelets to release several growth factors that induce vascular smooth muscle cell proliferation and intimal hyperplasia.[@b26-vhrm-5-843] All these abnormalities may contribute to the development of thrombotic complications.[@b7-vhrm-5-843],[@b24-vhrm-5-843]--[@b26-vhrm-5-843] *Ex vivo* studies also suggested that larger and loosely packed platelet thrombi are formed in the absence of fibrinogen.[@b27-vhrm-5-843] In some patients, the coexistence of thrombophilic disorders (eg, protein C deficiency, hepatitis C infection with mixed cryoglobulinemia and anticardiolipin antibodies) might also contribute to thrombosis.[@b28-vhrm-5-843],[@b29-vhrm-5-843] Fibrinogen also plays a role in wound healing, with reports of impaired wound healing following surgery and slow-healing leg ulcers in patients with afibrinogenemia.[@b3-vhrm-5-843],[@b30-vhrm-5-843],[@b31-vhrm-5-843] Spontaneous splenic rupture is another rare manifestation.[@b13-vhrm-5-843],[@b32-vhrm-5-843]--[@b34-vhrm-5-843]

Treatment
=========

Replacement therapy
-------------------

Replacement therapy is the mainstay of treatment of bleeding episodes in patients with afibrinogenemia and includes plasma-derived fibrinogen concentrate, cryoprecipitate and fresh frozen plasma (FFP).[@b5-vhrm-5-843],[@b35-vhrm-5-843],[@b36-vhrm-5-843] The quantity of fibrinogen required can be calculated as follows:
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Treatment should be administered daily or every other day based on the indication, response, potential fibrinogen consumption and monitoring of fibrinogen activity.[@b5-vhrm-5-843],[@b36-vhrm-5-843] Since the half-life of fibrinogen is approximately 4 days, alternate day administration should be sufficient in the absence of consumption.[@b36-vhrm-5-843] For spontaneous bleeding, recommended target fibrinogen levels are \>1 g/L until hemostasis is achieved and \>0.5 g/L until the bleeding surface is completely healed.[@b5-vhrm-5-843],[@b36-vhrm-5-843] However, many physicians appear to aim at higher fibrinogen levels possibly because of concerns about achieving hemostasis at lower levels; however, this strategy might increase the risk of thrombosis (see below).[@b12-vhrm-5-843]

Fibrinogen concentrate is the replacement therapy of choice in patients with afibrinogenemia.[@b35-vhrm-5-843],[@b36-vhrm-5-843] Its main advantage over other replacement therapies is that it is virally inactivated; other advantages are a smaller infusion volume and a lower risk of allergic reactions.[@b2-vhrm-5-843] Viral inactivation of existing fibrinogen concentrates is performed either with solvent detergent exposure (alone or in combination with dry heating and/or nanofiltration) or with pasteurization.[@b21-vhrm-5-843] However, non--lipid-enveloped viruses such as parvovirus B19 and hepatitis A virus may survive in currently used inactivation processes.[@b35-vhrm-5-843],[@b37-vhrm-5-843],[@b38-vhrm-5-843] Moreover, since all fibrinogen concentrates are plasma-derived, there is a theoretical potential for transmission of new non-viral pathogens (eg, prions).[@b21-vhrm-5-843],[@b35-vhrm-5-843] There are 5 fibrinogen concentrates currently available, Haemocomplettan^®^ P (CSL Behring, Marburg, Germany), Clottagen^®^ and FIBRINOGENE T1^®^ (LFB, Les Ullis, France), Fibrinogen HT^®^ (Benesis, Osaka, Japan) and FibroRAAS^®^ (Shangai RAAS, Shangai, China).[@b21-vhrm-5-843],[@b39-vhrm-5-843] These products are not available or licensed in all countries and there are no studies directly comparing their efficacy. In an open uncontrolled study, the half-life of Haemocomplettan P was between 2.5 and 5.2 days, ie, similar to the half-life of fibrinogen in normal individuals.[@b40-vhrm-5-843] A dose of 1 mg/kg Haemocomplettan P increased fibrinogen concentration by 0.015 g/L and normalized coagulation parameters during the day of infusion.[@b40-vhrm-5-843] In another open, uncontrolled, retrospective study, Haemocomplettan P was effective in both the treatment of spontaneous bleeding episodes and as prophylaxis before surgical procedures or against spontaneous bleeding.[@b41-vhrm-5-843] The median post-infusion fibrinogen levels were 1.45 g/L and a reduction in both thrombin and activated partial thromboplastin time was observed after infusion.[@b41-vhrm-5-843] The median single and total doses per episode were 2.0 and 4.0 g per patient, respectively, and the median duration of treatment was 1 day.[@b41-vhrm-5-843] One patient given prophylactic infusions developed an anaphylactic reaction and another patient undergoing osteosynthesis developed deep vein thrombosis and pulmonary embolism despite postoperative prophylaxis with heparin.[@b41-vhrm-5-843] No other side effects were reported.[@b41-vhrm-5-843] In a more recent open, uncontrolled, prospective study, target fibrinogen levels were achieved within 1 hour after the infusion of FIBRINOGENE T1 and the between-patient variability in pharmacokinetics was very small.[@b39-vhrm-5-843] The mean half-life of fibrinogen was 3.4 days and coagulation parameters were normalized for 6 to 10 days after the infusion.[@b39-vhrm-5-843] Administration of fibrinogen concentrate was also shown to correct platelet adhesion and ADP-induced platelet aggregation even at fibrinogen levels as low as 10% of normal.[@b8-vhrm-5-843]

Cryoprecipitate and FFP represent alternative replacement therapies and should be given only in emergencies when fibrinogen concentrate is not available.[@b21-vhrm-5-843],[@b35-vhrm-5-843],[@b36-vhrm-5-843] Cryoprecipitate and FFP can be either single donor or pooled.[@b35-vhrm-5-843] Single donor cryoprecipitate and FFP can be either virally inactivated (using methylene blue/visible light treatment) or non-virally inactivated.[@b35-vhrm-5-843] Pooled cryoprecipitate is non-virally inactivated whereas both virally inactivated (with solvent detergent treatment) and non-virally inactivated pooled FFP exist.[@b35-vhrm-5-843] However, the single-step viral inactivation of cryoprecipitate and FFP is considered inferior (particularly against non lipid-enveloped viruses) compared with fibrinogen concentrates that have undergone 2 viral inactivation steps.[@b35-vhrm-5-843] The amount of fibrinogen in cryoprecipitate and FFP varies but is lower than in fibrinogen concentrates.[@b12-vhrm-5-843] Cryoprecipitate is enriched in fibrinogen but methylene blue/visible light treatment of cryoprecipitate reduces fibrinogen activity by 40%.[@b35-vhrm-5-843] According to current guidelines, virally inactivated FFP should be preferred to non-virally inactivated cryoprecipitate unless volume overload poses unacceptable risks.[@b35-vhrm-5-843]

Thrombotic complications have been reported in patients with afibrinogenemia following replacement therapy, including ischemic foot lesions, ischemic stroke, renal and ovarian vein thrombosis, deep venous thrombosis and pulmonary embolism.[@b12-vhrm-5-843],[@b13-vhrm-5-843],[@b15-vhrm-5-843],[@b41-vhrm-5-843]--[@b44-vhrm-5-843] Patients with afibrinogenemia who also suffer from inherited thrombophilic disorders (eg, protein C deficiency) appear to be at higher risk for thrombosis after replacement therapy.[@b43-vhrm-5-843] In addition, the risk might be greater when cryoprecipitate is used since the latter contains substantial quantities of other coagulation factors (particularly von Willebrand factor and factor VIII).[@b21-vhrm-5-843] In patients with afibrinogenemia who exhibited thrombosis after cryoprecipitate treatment, switching to fibrinogen concentrate reduced the risk of recurrent thrombosis.[@b15-vhrm-5-843] The management of thrombotic complications in patients with afibrinogenemia is problematic because of their bleeding tendency. Some authors proposed the concomitant administration of replacement therapy with low-dose heparin.[@b43-vhrm-5-843] Others recommend use of compression stockings and low molecular weight heparin in patients with a history of thrombosis who are undergoing surgery.[@b21-vhrm-5-843] In patients who develop thrombotic complications following replacement therapy, some authors continue the latter if indicated and co-administer low-molecular-weight or unfractionated heparin.[@b13-vhrm-5-843],[@b15-vhrm-5-843] In patients who develop recurrent thrombotic complications despite treatment with heparin and aspirin, treatment with lepirudin, a direct thrombin inhibitor, appears to be effective.[@b45-vhrm-5-843]

In contrast to hemophilia, development of fibrinogen inhibitors following replacement therapy has been very rarely reported in patients with afibrinogenemia.[@b46-vhrm-5-843],[@b47-vhrm-5-843] It was suggested that the infrequent development of fibrinogen inhibitor is due to the presence of trace amounts of circulating fibrinogen.[@b21-vhrm-5-843]

Other treatments
================

Fibrin glue can be used in dental extractions and in superficial wounds.[@b36-vhrm-5-843] Tranexamic acid inhibits fibrinolysis by binding plasmin and might also be useful in the treatment of mucosal bleeding.[@b35-vhrm-5-843],[@b36-vhrm-5-843] It can be administered orally, intravenously or as a mouth wash.[@b35-vhrm-5-843] However, it might increase the risk of thrombosis and should be used with caution in patients with a history of thrombosis.[@b36-vhrm-5-843] It should also be avoided in pregnant women, in patients who had recently undergone surgery or are immobilized and in cases of hematuria.[@b35-vhrm-5-843],[@b36-vhrm-5-843] Tranexamic acid should be given at a lower dose in patients with renal failure.[@b35-vhrm-5-843]

In patients with splenic rupture, splenectomy after administering fibrinogen concentrate appears to be the treatment of choice.[@b32-vhrm-5-843],[@b48-vhrm-5-843] Conservative management with replacement therapy aiming at fibrinogen levels \>1 g/L has been reported in patients who are stable after fluid replacement. [@b34-vhrm-5-843] However, these patients appear to be at increased risk of recurrent splenic rupture.[@b48-vhrm-5-843]

In patients with severe liver disease mandating liver transplantation, the latter also will cure afibrinogenemia since fibrinogen is synthesized in the liver.[@b21-vhrm-5-843],[@b22-vhrm-5-843]

Prevention
==========

Before surgery, fibrinogen levels should be raised to 1 g/L and maintained at this level until hemostasis is established and above 0.5 g/L until complete wound healing.[@b36-vhrm-5-843] However, many physicians appear to aim at higher fibrinogen levels.[@b12-vhrm-5-843] All invasive procedures in patients with afibrinogenemia should take place in centers directly served by a hemophilia center.[@b36-vhrm-5-843]

Prophylactic infusion of fibrinogen concentrate or cryoprecipitate has been reported, particularly after life-threatening bleeding episodes.[@b12-vhrm-5-843]--[@b15-vhrm-5-843],[@b49-vhrm-5-843] Most patients are treated with weekly infusions but treatment every 2 weeks or once a month has also been used.[@b12-vhrm-5-843] However, the frequency of bleeding in an observational study was similar in patients treated on-demand and in those given prophylactic infusions.[@b12-vhrm-5-843] In the same study, more than half of the patients on prophylactic infusion experienced breakthrough bleeding, including intracranial hemorrhage.[@b12-vhrm-5-843] According to current guidelines, secondary prophylactic treatment may be considered after life-threatening bleeding (eg intracranial bleeding) with a target fibrinogen level of 0.5 g/L.[@b36-vhrm-5-843] Primary prophylactic infusion is not recommended because of the risk of transmission of infectious diseases and development of inhibitors, allergic reactions and thrombotic complications.[@b5-vhrm-5-843],[@b36-vhrm-5-843]

Estrogen-progesterone combination can be used as prophylaxis in patients with menorrhagia.[@b5-vhrm-5-843],[@b22-vhrm-5-843],[@b36-vhrm-5-843],[@b49-vhrm-5-843],[@b50-vhrm-5-843] Oral contraceptives also appear to be effective for the prevention of follicle rupture-induced hemoperitoneum.[@b18-vhrm-5-843],[@b19-vhrm-5-843] However, oral contraceptives might increase the risk of thrombosis.[@b22-vhrm-5-843],[@b51-vhrm-5-843] Antifibrinolytic agents (eg, tranexamic acid and aminocaproic acid) can be used as prophylaxis before dental procedures.[@b5-vhrm-5-843],[@b36-vhrm-5-843] Intramuscular injections should be avoided in patients with afibrinogenemia.[@b5-vhrm-5-843] Patients should be vaccinated against hepatitis A and B by subcutaneous injection.[@b36-vhrm-5-843] Prenatal diagnosis is possible when both parents are known heterozygotes for afibrinogenemia mutations or already have an affected child.[@b52-vhrm-5-843]

Pregnancy
=========

Fibrinogen appears to contribute to placental implantation.[@b53-vhrm-5-843] Accordingly, there is an increased risk of spontaneous abortion in patients with afibrinogenemia, which occurs at 6 to 8 weeks of gestation if no replacement therapy is given.[@b3-vhrm-5-843],[@b12-vhrm-5-843],[@b53-vhrm-5-843]--[@b56-vhrm-5-843] Patients with afibrinogenemia can have successful pregnancies if treated with fibrinogen concentrate or cryoprecipitate.[@b3-vhrm-5-843],[@b13-vhrm-5-843],[@b49-vhrm-5-843],[@b53-vhrm-5-843],[@b55-vhrm-5-843],[@b57-vhrm-5-843],[@b58-vhrm-5-843] However, preterm delivery appears to be more frequent in these women despite replacement therapy.[@b53-vhrm-5-843] Placental abruption has also been reported despite the administration of fibrinogen concentrate or cryoprecipitate.[@b13-vhrm-5-843],[@b58-vhrm-5-843]

Replacement therapy should be instituted as soon as possible in pregnancy in order to prevent fetal loss, probably from the 5th week of gestation.[@b5-vhrm-5-843],[@b36-vhrm-5-843],[@b53-vhrm-5-843] It should be continued throughout the pregnancy aiming at fibrinogen levels \>1.0 g/L.[@b36-vhrm-5-843] Hemorrhagic complications have been reported with lower fibrinogen levels.[@b49-vhrm-5-843] However, thrombotic complications have also been reported during replacement therapy in pregnancy.[@b13-vhrm-5-843] It appears that fibrinogen requirements increase as pregnancy progresses.[@b13-vhrm-5-843],[@b53-vhrm-5-843] During labor, some authors recommend higher levels (\>2.0 g/L) to prevent placental abruption.[@b53-vhrm-5-843] Both vaginal delivery and cesarean sections have been reported.[@b53-vhrm-5-843],[@b59-vhrm-5-843] During puerperium, lower fibrinogen levels appear to be sufficient to prevent bleeding.[@b53-vhrm-5-843] Pregnancy should be managed in obstetric departments of hospitals that have a hemophilia center.[@b36-vhrm-5-843]

Conclusions
===========

Even though afibrinogenemia is a rare disorder, it might acquire greater importance in the future because of the immigration of Islamic populations where this disorder is more prevalent due to consanguineous marriages.[@b60-vhrm-5-843] Patients with afibrinogenemia should be referred to and registered with a hemophilia center.[@b36-vhrm-5-843] The development of new tests to identify higher risk patients and of safer replacement therapy will improve the management of these patients in the future.
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